All In Biotech

Drug Trial Radar · NCT05358717

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease

Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Jun 3, 2022

Primary completion

Feb 7, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

Conditions

  • Huntington Disease

Interventions

  • PTC518Drug

    PTC518 will be administered per dose and schedule specified in the arm.

  • PlaceboDrug

    Placebo matching to PTC518 will be administered per schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Month 18
  2. Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3Time frame: Baseline, Month 3

Locations

28 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California, San Diego

    La Jolla, California

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas Health Science Center at Houston; McGovern Medical School

    Houston, Texas

  • University of Washington Department of Neurology

    Seattle, Washington

  • Monash Health

    Clayton, Australia

  • Westmead Hospital

    Sydney, Australia

  • Medical University Innsbruck

    Innsbruck, Austria

  • The Ottawa Hospital, Parkinson's and Movement Disorders Clinic

    Ottawa, Canada

  • Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Hôpital Universitaire de Marseille Hôpital de la Timone

    Marseille, France

  • Brain and Spine Institute Paris

    Paris, France

  • Charite University Medicine Berlin

    Berlin, Germany

  • Ruhr-Univ. Bochum St. Joseph-Hospital

    Bochum, Germany

  • George-Huntington-Institut

    Münster, Germany

  • Ulm University, UKU, Dep. of Neurology

    Ulm, Germany

  • Irccs Istituto Delle Scienze Neurologiche Di Bologna Uoc Clinica Neurologica

    Bologna, Italy

  • IRCCS Carlo Besta Neurological Institutte

    Milan, Italy

  • IRCCS Casa Sollievo della Sofferenza Research Hospital

    San Giovanni Rotondo, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • University of Otago, New Zealand Brain Research Institute

    Christchurch, New Zealand

  • Hospital Universitario Cruces

    Barakaldo, Spain

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, Spain

  • Hospital Universitario Burgos

    Burgos, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • The Barbery National Centre for Mental Health

    Birmingham, United Kingdom

  • Cardiff University Schools of Medicine and Biosciences

    Cardiff, United Kingdom

  • UCL Queen Square Institute of Neurology National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.